title: Dimensions of schizophrenia and their time course of response to a second generation antipsychotic olanzapine-A clinical study.
abstract: BACKGROUND
  The pattern of symptom response to second generation antipsychotics (SGAs) has not been studied extensively. Understanding the time course of symptom response would help to rationally monitor patient progress.
  
  
  OBJECTIVE
  To determine the short-term differential time course of response of symptom dimensions of first episode schizophrenia viz., negative, positive symptoms and 5 factors of anergia, thought disturbance, activation, paranoid-belligerence and depression to treatment with SGA olanzapine.
  
  
  METHODS
  57 drug naive patients with schizophrenia were treated for 4 weeks with olanzapine 10mg/day, increased to 20mg/day in 1 week. Weight was recorded and ratings with the Positive and Negative Syndrome scale (PANSS), the Simpson Angus Scale (SAS) were performed weekly.
  
  
  RESULTS
  43 patients completed 4 weeks of assessment. Scores on all of the dimensions improved. By the end of week 1, only positive syndrome, thought disturbance and paranoid-belligerence dimensions improved. Maximum improvement was seen with paranoid-belligerence by week 1, followed by positive syndrome in week 2, and depression at week 3. The percentage improvement in positive syndrome was significantly greater than negative. Over 4 weeks there was a mean weight gain of 2kg and there were significant extrapyramidal symptoms.
  
  
  CONCLUSIONS
  Olanzapine produced reduction in all dimensions, but the pace of responding of individual dimensions differed. Longer-term studies comparing SGAs with first generation antipsychotics are needed.
authors.affiliation: Department of Psychiatry, University of Alabama Birmingham (UAB), Birmingham, AL, United States. Electronic address: bbirur@uabmc.edu.
authors.forename: Badari
authors.initials: B
authors.lastname: Birur
authors.affiliation: National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India.
authors.forename: Jagadisha
authors.initials: J
authors.lastname: Thirthalli
authors.affiliation: National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India.
authors.forename: N
authors.initials: N
authors.lastname: Janakiramaiah
authors.affiliation: Department of Psychiatry, University of Alabama Birmingham (UAB), Birmingham, AL, United States.
authors.forename: Richard C
authors.initials: RC
authors.lastname: Shelton
authors.affiliation: National Institute of Mental Health and Neuro Sciences (NIMHANS), Bangalore, India.
authors.forename: Bangalore N
authors.initials: BN
authors.lastname: Gangadhar
mesh_terms: D000293:Adolescent; D000328:Adult; D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001569:Benzodiazepines / Q000008:administration & dosage / Q000494:pharmacology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D017063:Outcome Assessment, Health Care; D012559:Schizophrenia / Q000188:drug therapy* / Q000503:physiopathology*; D013997:Time Factors; D055815:Young Adult
chemical_list: D014150:Antipsychotic Agents; D001569:Benzodiazepines; D000077152:Olanzapine
keywords: Dimensions; Drug naïve; First episode schizophrenia; Second generation antipsychotic olanzapine